BackStericycle Overview

Stericycle Other Liabilities

Track Stericycle's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Stericycle Other Liabilities History

Loading

Stericycle vs. peers: Other Liabilities Comparison

Loading

Stericycle Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Stericycle (SRCL) FAQ

Stericycle (SRCL) currently reports a other liabilities of $0 as of September 2024. In the prior-year period, the figure was $0. Use the charts on this page to explore Stericycle's other liabilities history and peer comparisons.

Stericycle's other liabilities changed from $0 to $0 (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Stericycle reported $0 in other liabilities as of September 2024. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Stericycle, and consider following SRCL for alerts when major investors trade the stock.

Stericycle is classified in the Industrials sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing SRCL with unrelated industries.